[P25-9] P25-9: Oncologic drugs (1)

[P25-9-4] Quantification method for immune check point inhibitor, Nivolumab, using liquid chromatography tandem mass spectrometry

Irie Kei¹, Yuta Yamasaki², Seika Hiratsuji³, Yutaka Okada⁴, Shuichi Kishimoto⁵, Shoji Fukushima⁶ (1.Institute of Biomedical Research and Innovation, 2.Kobe Gakuin University, 3.Kobe Gakuin University, 4.Institute of Biomedical Research and Innovation, 5.Kobe Gakuin University, 6.Kobe Gakuin University)

Keywords:nivolumab, immune check point inhibitor, LC-MS/MS